Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

The Trump administration is preparing to impose new tariffs on drugmakers that have not agreed to lower U.S. drug prices with the president. This introduces heightened regulatory and political risk for pharmaceutical companies and could pressure sector revenues and margins if tariffs are applied. Expect increased negotiation activity between the White House and drug companies and potential near-term downside risk to valuations for firms that refuse deals; monitor announced tariff rates and targeted companies.

Analysis

The Trump administration is preparing to impose new tariffs on drugmakers that have not agreed to lower U.S. drug prices with the president. This introduces heightened regulatory and political risk for pharmaceutical companies and could pressure sector revenues and margins if tariffs are applied. Expect increased negotiation activity between the White House and drug companies and potential near-term downside risk to valuations for firms that refuse deals; monitor announced tariff rates and targeted companies.